NeoLAB® Solid Tumor Liquid Biopsy

  • Liquid Biopsy
The NeoLAB Solid Tumor Liquid Biopsy is a next-gen sequencing assay designed to detect mutations in cell-free circulating tumor DNA of patients with solid tumors (pan-cancer). Analytic validation demonstrated accuracy of 98.0%, sensitivity of 95.1%, and specificity of 98.8%. SNVs and indels (969 mutations across these 44 genes): AKT1, ALK, APC, AR, ARAF, BRAF, CHEK2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (aka MEK1), MAP2K2 (aka MEK2), MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, SF3B1, SMAD4, SMO, and TP53. NOTE: Not available for samples from New York.
Turnaround time
7 to 10 Days

Level of Service

  • Global
New York Approved: No

Specimen Requirements

Peripheral blood: two x 10 mL Streck Cell-Free DNA BCT® tubes

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*

81445

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Last Updated: January 22, 2025

Get in touch

Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.